Retatrutide Outperforms Ozempic in Diabetes Trial, But Side Effects Persist

Key points

• Retatrutide users lost an average of 44.3 to 47.4 pounds, compared to 20.9 pounds for Ozempic users.
• A1C levels dropped by 2.2% for retatrutide versus 1.8% for Ozempic.
• Discontinuation due to side effects was 7.9% for the 12mg retatrutide dose versus 2.7% for Ozempic.
• Retatrutide is a triple agonist mimicking GIP, GLP-1, and glucagon, whereas Ozempic targets only GLP-1.

Background

This follows recent reports of retatrutide's benefits for sleep apnea and warnings about contaminated black-market versions. The current trial adds to a growing body of evidence regarding next-generation GLP-1 therapies.

How outlets are covering it

USA Today and ABC News emphasized the superior efficacy of retatrutide in weight loss and blood sugar control. WXLV highlighted the trade-off, noting that while retatrutide offered better results, it caused more side effects, leading to higher dropout rates. Novo Nordisk's spokesperson countered that Ozempic offers broader organ protection and a longer safety profile, noting its use by 28 million people worldwide.

Why it matters

The results suggest a potential shift in the market for obesity and diabetes treatments, with retatrutide offering more potent effects but requiring careful management of side effects. This could impact future prescribing guidelines and patient choices.

What to watch

Eli Lilly intends to submit retatrutide for FDA approval in early 2027. Detailed results will be presented at a future medical meeting and published in a peer-reviewed journal. Novo Nordisk is also awaiting approval for its experimental drug CagriSema by the end of 2026.